GR1008838B - Method for the combination of pharmaceutical substances exhibiting multi-factor inhibitory activity against neoplasms and innunostimulants for the same purpose - Google Patents

Method for the combination of pharmaceutical substances exhibiting multi-factor inhibitory activity against neoplasms and innunostimulants for the same purpose

Info

Publication number
GR1008838B
GR1008838B GR20150100211A GR20150100211A GR1008838B GR 1008838 B GR1008838 B GR 1008838B GR 20150100211 A GR20150100211 A GR 20150100211A GR 20150100211 A GR20150100211 A GR 20150100211A GR 1008838 B GR1008838 B GR 1008838B
Authority
GR
Greece
Prior art keywords
combination
medications
innunostimulants
inhibitory activity
activity against
Prior art date
Application number
GR20150100211A
Other languages
Greek (el)
Inventor
Νικολαος Χρηστου Δημοφιλος
Original Assignee
Νικολαος Χρηστου Δημοφιλος
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Νικολαος Χρηστου Δημοφιλος filed Critical Νικολαος Χρηστου Δημοφιλος
Priority to GR20150100211A priority Critical patent/GR1008838B/en
Publication of GR1008838B publication Critical patent/GR1008838B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/889—Arecaceae, Palmae or Palmaceae (Palm family), e.g. date or coconut palm or palmetto
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

Combination of simple chronically and daily-used medications of recognized theurapetical utility with a few other medications of general (but not precise) antineoplasmatic use for the multilateral targeted destruction of cancer is disclosed. Said methodological combinational approach is based on new data regarding the hidden advantages of the plurality of medicines we have used for the destruction and modification of signal transductions and metastatic routes. The advantages are documented by reliable international reputation centers. Some of these medications exhibit synergic anticancer activity as referred in international bibliography. Their utilization over the years has yielded excellent results free of cross-hypersensitivity reactions, conserving over the years the achieved results.
GR20150100211A 2015-05-13 2015-05-13 Method for the combination of pharmaceutical substances exhibiting multi-factor inhibitory activity against neoplasms and innunostimulants for the same purpose GR1008838B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GR20150100211A GR1008838B (en) 2015-05-13 2015-05-13 Method for the combination of pharmaceutical substances exhibiting multi-factor inhibitory activity against neoplasms and innunostimulants for the same purpose

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GR20150100211A GR1008838B (en) 2015-05-13 2015-05-13 Method for the combination of pharmaceutical substances exhibiting multi-factor inhibitory activity against neoplasms and innunostimulants for the same purpose

Publications (1)

Publication Number Publication Date
GR1008838B true GR1008838B (en) 2016-09-05

Family

ID=58186184

Family Applications (1)

Application Number Title Priority Date Filing Date
GR20150100211A GR1008838B (en) 2015-05-13 2015-05-13 Method for the combination of pharmaceutical substances exhibiting multi-factor inhibitory activity against neoplasms and innunostimulants for the same purpose

Country Status (1)

Country Link
GR (1) GR1008838B (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6200573B1 (en) * 1999-12-03 2001-03-13 Starcor Pharmaceuticals, Inc. Method of medical management for lower urinary tract symptoms and benign prostatic hyperplasia
US6573290B1 (en) * 1999-05-17 2003-06-03 Ilex Oncology, Inc. DFMO and celecoxib in combination for cancer chemoprevention and therapy
US20030232033A1 (en) * 2002-02-21 2003-12-18 Cantrell Stephen B. Interferon-statin combination therapy
GR1006664B (en) * 2008-10-16 2010-01-15 Νικολαος Χρηστου Δημοφιλος Complex forulation which decomposes in the intensive for prophylaxis against mutagenic effects and secondarily after surgery of intestinal tumours in high-risk populations.
US20140294994A1 (en) * 2011-10-28 2014-10-02 Ch-Ying Huang Pharmaceutical composition for elimination of cancer stem cells

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6573290B1 (en) * 1999-05-17 2003-06-03 Ilex Oncology, Inc. DFMO and celecoxib in combination for cancer chemoprevention and therapy
US6200573B1 (en) * 1999-12-03 2001-03-13 Starcor Pharmaceuticals, Inc. Method of medical management for lower urinary tract symptoms and benign prostatic hyperplasia
US20030232033A1 (en) * 2002-02-21 2003-12-18 Cantrell Stephen B. Interferon-statin combination therapy
GR1006664B (en) * 2008-10-16 2010-01-15 Νικολαος Χρηστου Δημοφιλος Complex forulation which decomposes in the intensive for prophylaxis against mutagenic effects and secondarily after surgery of intestinal tumours in high-risk populations.
US20140294994A1 (en) * 2011-10-28 2014-10-02 Ch-Ying Huang Pharmaceutical composition for elimination of cancer stem cells

Similar Documents

Publication Publication Date Title
USD728601S1 (en) Glucometer with a data sharing screen graphical user interface
TW201614068A (en) Fucosidase from bacteroides and methods using the same
EP3155515A4 (en) Computer-implemented tools and methods for extracting information about the structure of a large computer software system, exploring its structure, discovering problems in its design, and enabling refactoring
MX347822B (en) Geometrical presentation of fracture planes.
WO2015119691A3 (en) Client-configurable security options for data streams
CA149200S (en) Needle-free syringe
GB2526984A (en) Secure digital artifact storage and access
BR112015023203A8 (en) methods for treating cancer, method for increasing the efficiency of cancer treatment, method for delaying and / or preventing cancer development, method for treating an individual with cancer, method for increasing sensitivity for a cancer therapy agent, method for extending a sensitivity period and method for extending the duration of response to cancer therapy.
MX2015003141A (en) Analyzing fracture stratigraphy.
GB2534272A (en) Rotationally-independent wellbore ranging
AU201811196S (en) A toaster
CL2013003230A1 (en) Use of volasertib, a salt or a hydrate thereof to prepare a drug useful in the treatment of advanced and / or metastatic solid tumors.
EP3033150A4 (en) Administration of karenitecin for the treatment of advanced ovarian cancer, including chemotherapy-resistant and/or the mucinous adenocarcinoma sub-types
WO2015009591A3 (en) Treatment for melanoma
CL2013003198A1 (en) Use of volasertib, a salt or a hydrate thereof to prepare a drug useful in the treatment of solid malignancies that include advanced and metastatic solid malignancies.
WO2015066212A3 (en) Calpain inhibitors for ibd and colorectal cancer treatment
CO2020003977A2 (en) Nitrogen-containing heteroaryl compound, and its pharmaceutical use
MX2017002323A (en) Disintegrin variants and pharmaceutical uses thereof.
MX2015010286A (en) Anise flavored medication.
GR1008838B (en) Method for the combination of pharmaceutical substances exhibiting multi-factor inhibitory activity against neoplasms and innunostimulants for the same purpose
NZ608851A (en) Ordering rays in rendered graphics for coherent shading
Sta Application
FI20145456A (en) Arrangements, procedures and computer programs for checking security in the elderly
Shevchenko Theoretical grounding of practical mechanisms of public-private partnership within innovative sector of national economy
Ross Guerrilla Girls Gig Poster

Legal Events

Date Code Title Description
PG Patent granted

Effective date: 20161020